Compare TransMedics Group Inc (TMDX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? TransMedics Group Inc trades at $74.84 (market cap $2.54B), while Vanguard S&P 500 Growth Index Fund ETF trades at $82.02. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VOOG | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $150.42 | $85.11 |
52-Week Low | $61.99 | $65.32 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $80.98, up 0.28% on the day. The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent news highlights its competitive expense ratio of 0.07% and heavy technology sector concentration, which has driven strong long-term returns but also introduces volatility. A 1:6 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 26, 2026.
The ETF's outlook hinges on the performance of large-cap growth stocks, particularly in technology. Opportunities exist from continued AI-driven growth, but risks include high sector concentration and market sensitivity to tech valuations. Analyst sentiment is generally positive given its low-cost structure and historical performance, though the current bearish technical signal warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
